# Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets

> **NCT06484673** · PHASE1 · COMPLETED · sponsor: **Humanis Saglık Anonim Sirketi** · enrollment: 32 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Bosentan Dispersible Tablets
- **DRUG:** Tracleer Tablet for Oral Suspension

## Key facts

- **NCT ID:** NCT06484673
- **Lead sponsor:** Humanis Saglık Anonim Sirketi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-21
- **Primary completion:** 2024-05-22
- **Final completion:** 2024-05-27
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06484673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06484673, "Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06484673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*